AU2018331267B2 - Improved treatment of atopic dermatitis with tradipitant - Google Patents
Improved treatment of atopic dermatitis with tradipitant Download PDFInfo
- Publication number
- AU2018331267B2 AU2018331267B2 AU2018331267A AU2018331267A AU2018331267B2 AU 2018331267 B2 AU2018331267 B2 AU 2018331267B2 AU 2018331267 A AU2018331267 A AU 2018331267A AU 2018331267 A AU2018331267 A AU 2018331267A AU 2018331267 B2 AU2018331267 B2 AU 2018331267B2
- Authority
- AU
- Australia
- Prior art keywords
- patient
- tradipitant
- rsl
- treatment
- genotype
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- CAVRKWRKTNINFF-UHFFFAOYSA-N [2-[1-[[3,5-bis(trifluoromethyl)phenyl]methyl]-5-pyridin-4-yltriazol-4-yl]pyridin-3-yl]-(2-chlorophenyl)methanone Chemical compound FC(F)(F)C1=CC(C(F)(F)F)=CC(CN2C(=C(N=N2)C=2C(=CC=CN=2)C(=O)C=2C(=CC=CC=2)Cl)C=2C=CN=CC=2)=C1 CAVRKWRKTNINFF-UHFFFAOYSA-N 0.000 title claims abstract description 204
- 229950011232 tradipitant Drugs 0.000 title claims abstract description 202
- 238000011282 treatment Methods 0.000 title claims abstract description 125
- 206010012438 Dermatitis atopic Diseases 0.000 title claims abstract description 90
- 201000008937 atopic dermatitis Diseases 0.000 title claims abstract description 90
- 238000000034 method Methods 0.000 claims abstract description 67
- 208000003251 Pruritus Diseases 0.000 claims description 95
- 230000004044 response Effects 0.000 claims description 42
- 230000000694 effects Effects 0.000 claims description 40
- 230000006872 improvement Effects 0.000 claims description 32
- 102220590275 Butyrophilin-like protein 2_M380I_mutation Human genes 0.000 claims description 14
- 102220590274 Butyrophilin-like protein 2_P379L_mutation Human genes 0.000 claims description 14
- 102220590279 Butyrophilin-like protein 2_P393Q_mutation Human genes 0.000 claims description 14
- 239000012472 biological sample Substances 0.000 claims description 9
- 101100271190 Plasmodium falciparum (isolate 3D7) ATAT gene Proteins 0.000 claims description 8
- 208000010216 atopic IgE responsiveness Diseases 0.000 claims description 6
- 238000012360 testing method Methods 0.000 claims description 4
- 208000024891 symptom Diseases 0.000 abstract description 9
- 102100022706 Interleukin-20 receptor subunit alpha Human genes 0.000 description 48
- 101710174006 Interleukin-20 receptor subunit alpha Proteins 0.000 description 48
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 27
- 239000000902 placebo Substances 0.000 description 23
- 229940068196 placebo Drugs 0.000 description 23
- 230000036470 plasma concentration Effects 0.000 description 19
- 238000004458 analytical method Methods 0.000 description 17
- 201000010099 disease Diseases 0.000 description 13
- 230000008859 change Effects 0.000 description 11
- 239000003795 chemical substances by application Substances 0.000 description 10
- 230000002068 genetic effect Effects 0.000 description 10
- 230000001684 chronic effect Effects 0.000 description 9
- 102100028918 Catenin alpha-3 Human genes 0.000 description 8
- 101000916179 Homo sapiens Catenin alpha-3 Proteins 0.000 description 8
- 208000035475 disorder Diseases 0.000 description 8
- 108700028369 Alleles Proteins 0.000 description 7
- 102100037346 Substance-P receptor Human genes 0.000 description 7
- 230000008901 benefit Effects 0.000 description 7
- 239000002245 particle Substances 0.000 description 7
- 102100024304 Protachykinin-1 Human genes 0.000 description 6
- 101800003906 Substance P Proteins 0.000 description 6
- 101710097909 Substance-P receptor Proteins 0.000 description 6
- 108090000623 proteins and genes Proteins 0.000 description 6
- 210000001519 tissue Anatomy 0.000 description 6
- QDZOEBFLNHCSSF-PFFBOGFISA-N (2S)-2-[[(2R)-2-[[(2S)-1-[(2S)-6-amino-2-[[(2S)-1-[(2R)-2-amino-5-carbamimidamidopentanoyl]pyrrolidine-2-carbonyl]amino]hexanoyl]pyrrolidine-2-carbonyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-N-[(2R)-1-[[(2S)-1-[[(2R)-1-[[(2S)-1-[[(2S)-1-amino-4-methyl-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]pentanediamide Chemical compound C([C@@H](C(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(N)=O)NC(=O)[C@@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](N)CCCNC(N)=N)C1=CC=CC=C1 QDZOEBFLNHCSSF-PFFBOGFISA-N 0.000 description 5
- 201000004624 Dermatitis Diseases 0.000 description 5
- 108060003951 Immunoglobulin Proteins 0.000 description 5
- 239000012729 immediate-release (IR) formulation Substances 0.000 description 5
- 102000018358 immunoglobulin Human genes 0.000 description 5
- 230000000007 visual effect Effects 0.000 description 5
- 206010015150 Erythema Diseases 0.000 description 4
- 101000599573 Homo sapiens InaD-like protein Proteins 0.000 description 4
- 206010020751 Hypersensitivity Diseases 0.000 description 4
- 239000008186 active pharmaceutical agent Substances 0.000 description 4
- 238000003556 assay Methods 0.000 description 4
- 208000010668 atopic eczema Diseases 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 230000008482 dysregulation Effects 0.000 description 4
- 239000003607 modifier Substances 0.000 description 4
- 102220313493 rs746811389 Human genes 0.000 description 4
- 238000006748 scratching Methods 0.000 description 4
- 230000002393 scratching effect Effects 0.000 description 4
- 210000003491 skin Anatomy 0.000 description 4
- -1 3,5-bis-trifluoromethylphenyl moiety Chemical group 0.000 description 3
- 208000035874 Excoriation Diseases 0.000 description 3
- 102100037978 InaD-like protein Human genes 0.000 description 3
- 206010024438 Lichenification Diseases 0.000 description 3
- 208000026935 allergic disease Diseases 0.000 description 3
- 230000001668 ameliorated effect Effects 0.000 description 3
- 208000006673 asthma Diseases 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 239000000969 carrier Substances 0.000 description 3
- 238000013270 controlled release Methods 0.000 description 3
- 230000002596 correlated effect Effects 0.000 description 3
- 231100000321 erythema Toxicity 0.000 description 3
- 230000014509 gene expression Effects 0.000 description 3
- 230000000051 modifying effect Effects 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 210000001578 tight junction Anatomy 0.000 description 3
- 206010003645 Atopy Diseases 0.000 description 2
- 101000984620 Homo sapiens Low-density lipoprotein receptor-related protein 1B Proteins 0.000 description 2
- 102100027121 Low-density lipoprotein receptor-related protein 1B Human genes 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 206010030113 Oedema Diseases 0.000 description 2
- 230000007815 allergy Effects 0.000 description 2
- 239000005557 antagonist Substances 0.000 description 2
- 238000012098 association analyses Methods 0.000 description 2
- 230000036765 blood level Effects 0.000 description 2
- 230000037058 blood plasma level Effects 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 230000007803 itching Effects 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 230000001537 neural effect Effects 0.000 description 2
- 230000007310 pathophysiology Effects 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 210000002381 plasma Anatomy 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- 230000035807 sensation Effects 0.000 description 2
- 238000009097 single-agent therapy Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- QWENRTYMTSOGBR-UHFFFAOYSA-N 1H-1,2,3-Triazole Chemical group C=1C=NNN=1 QWENRTYMTSOGBR-UHFFFAOYSA-N 0.000 description 1
- FPYUJUBAXZAQNL-UHFFFAOYSA-N 2-chlorobenzaldehyde Chemical compound ClC1=CC=CC=C1C=O FPYUJUBAXZAQNL-UHFFFAOYSA-N 0.000 description 1
- 101150072006 33 gene Proteins 0.000 description 1
- 108091022885 ADAM Proteins 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 101150076489 B gene Proteins 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 102100025429 Butyrophilin-like protein 2 Human genes 0.000 description 1
- 102000000905 Cadherin Human genes 0.000 description 1
- 108050007957 Cadherin Proteins 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 102100021396 Cell surface glycoprotein CD200 receptor 1 Human genes 0.000 description 1
- 108010077544 Chromatin Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 102000016911 Deoxyribonucleases Human genes 0.000 description 1
- 108010053770 Deoxyribonucleases Proteins 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 208000004262 Food Hypersensitivity Diseases 0.000 description 1
- 206010016946 Food allergy Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000934738 Homo sapiens Butyrophilin-like protein 2 Proteins 0.000 description 1
- 101000969553 Homo sapiens Cell surface glycoprotein CD200 receptor 1 Proteins 0.000 description 1
- 101000969961 Homo sapiens Neurexin-3 Proteins 0.000 description 1
- 101000969963 Homo sapiens Neurexin-3-beta Proteins 0.000 description 1
- 101000577224 Homo sapiens Neuropeptide S receptor Proteins 0.000 description 1
- 101000585623 Homo sapiens Unconventional myosin-X Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102100022723 Interleukin-22 receptor subunit alpha-1 Human genes 0.000 description 1
- 108010001831 LDL receptors Proteins 0.000 description 1
- 108090001030 Lipoproteins Proteins 0.000 description 1
- 102000004895 Lipoproteins Human genes 0.000 description 1
- 102100024640 Low-density lipoprotein receptor Human genes 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 206010028817 Nausea and vomiting symptoms Diseases 0.000 description 1
- 102100021310 Neurexin-3 Human genes 0.000 description 1
- 208000007920 Neurogenic Inflammation Diseases 0.000 description 1
- 229940123821 Neurokinin 1 receptor antagonist Drugs 0.000 description 1
- 108010040718 Neurokinin-1 Receptors Proteins 0.000 description 1
- 102000000470 PDZ domains Human genes 0.000 description 1
- 108050008994 PDZ domains Proteins 0.000 description 1
- 206010033733 Papule Diseases 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical group C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 108010002321 Tight Junction Proteins Proteins 0.000 description 1
- 102000000591 Tight Junction Proteins Human genes 0.000 description 1
- 102100029827 Unconventional myosin-X Human genes 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 206010048222 Xerosis Diseases 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 230000017455 cell-cell adhesion Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 208000029771 childhood onset asthma Diseases 0.000 description 1
- 125000000068 chlorophenyl group Chemical group 0.000 description 1
- 210000003483 chromatin Anatomy 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 235000019788 craving Nutrition 0.000 description 1
- 238000002790 cross-validation Methods 0.000 description 1
- 102000003675 cytokine receptors Human genes 0.000 description 1
- 108010057085 cytokine receptors Proteins 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 210000003979 eosinophil Anatomy 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 238000011985 exploratory data analysis Methods 0.000 description 1
- 235000020932 food allergy Nutrition 0.000 description 1
- 238000010199 gene set enrichment analysis Methods 0.000 description 1
- 238000003205 genotyping method Methods 0.000 description 1
- 230000009610 hypersensitivity Effects 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 102000004114 interleukin 20 Human genes 0.000 description 1
- 108090000681 interleukin 20 Proteins 0.000 description 1
- 108010027445 interleukin-22 receptor Proteins 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 238000012417 linear regression Methods 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- WSFSSNUMVMOOMR-BJUDXGSMSA-N methanone Chemical compound O=[11CH2] WSFSSNUMVMOOMR-BJUDXGSMSA-N 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- PFPSZGPAQFBVHZ-UHFFFAOYSA-N n-(3-chlorophenyl)-2-[(4-phenyl-5-pyridin-4-yl-1,2,4-triazol-3-yl)sulfanyl]acetamide Chemical compound ClC1=CC=CC(NC(=O)CSC=2N(C(C=3C=CN=CC=3)=NN=2)C=2C=CC=CC=2)=C1 PFPSZGPAQFBVHZ-UHFFFAOYSA-N 0.000 description 1
- 239000002742 neurokinin 1 receptor antagonist Substances 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 230000036407 pain Effects 0.000 description 1
- 230000037324 pain perception Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000008447 perception Effects 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 102000054765 polymorphisms of proteins Human genes 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 230000001823 pruritic effect Effects 0.000 description 1
- 229940044551 receptor antagonist Drugs 0.000 description 1
- 239000002464 receptor antagonist Substances 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 208000034207 response to glucocorticoid therapy Diseases 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 210000004927 skin cell Anatomy 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 230000036620 skin dryness Effects 0.000 description 1
- 230000004622 sleep time Effects 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000007909 solid dosage form Substances 0.000 description 1
- 210000000434 stratum corneum Anatomy 0.000 description 1
- 201000006152 substance dependence Diseases 0.000 description 1
- 208000011117 substance-related disease Diseases 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000001364 upper extremity Anatomy 0.000 description 1
- 230000001755 vocal effect Effects 0.000 description 1
- 238000012070 whole genome sequencing analysis Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762558303P | 2017-09-13 | 2017-09-13 | |
| US62/558,303 | 2017-09-13 | ||
| US201762572456P | 2017-10-14 | 2017-10-14 | |
| US62/572,456 | 2017-10-14 | ||
| PCT/US2018/048825 WO2019055225A1 (en) | 2017-09-13 | 2018-08-30 | ENHANCED TREATMENT OF ATOPIC DERMATITIS USING TRADIPITANT |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2018331267A1 AU2018331267A1 (en) | 2020-04-16 |
| AU2018331267B2 true AU2018331267B2 (en) | 2024-03-07 |
Family
ID=63684468
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2018331267A Active AU2018331267B2 (en) | 2017-09-13 | 2018-08-30 | Improved treatment of atopic dermatitis with tradipitant |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US11549147B2 (es) |
| EP (1) | EP3681505A1 (es) |
| JP (1) | JP7347743B2 (es) |
| KR (1) | KR20200054232A (es) |
| CN (1) | CN111093671A (es) |
| AU (1) | AU2018331267B2 (es) |
| BR (1) | BR112020004964A2 (es) |
| CA (1) | CA3073998A1 (es) |
| CL (1) | CL2020000655A1 (es) |
| IL (1) | IL272949A (es) |
| MX (1) | MX2020002852A (es) |
| WO (1) | WO2019055225A1 (es) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112017018620A2 (pt) * | 2015-03-04 | 2018-04-17 | Vanda Pharmaceuticals Inc. | método de administração de tradipitanto, e, tradipitanto. |
| US20210228555A1 (en) | 2018-06-08 | 2021-07-29 | Vanda Pharmaceuticals Inc. | Method of treatment with tradipitant |
| MX2022010437A (es) * | 2020-02-25 | 2022-09-07 | Vanda Pharmaceuticals Inc | Tratamiento mejorado de la dermatitis atopica con tradipitant. |
| US20230145932A1 (en) | 2020-03-26 | 2023-05-11 | Vanda Pharmaceuticals Inc. | Treatment of lower respiratory tract infection with tradipitant |
| US20220328808A1 (en) | 2020-05-07 | 2022-10-13 | Lg Energy Solution, Ltd. | High-nickel electrode sheet and method for manufacturing same |
| WO2023034718A1 (en) | 2021-08-31 | 2023-03-09 | Vanda Pharmaceuticals Inc. | Treatment of lower respiratory tract infection with tradipitant |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW263498B (es) | 1993-11-10 | 1995-11-21 | Takeda Pharm Industry Co Ltd | |
| CA2483159C (en) | 2002-04-26 | 2010-08-10 | Eli Lilly And Company | Triazole derivatives as tachykinin receptor antagonists |
| BR0309486A (pt) | 2002-04-26 | 2005-02-09 | Lilly Co Eli | Composto ou um seu sal farmaceuticamente aceitável, composição farmacêutica, e, método para o tratamento de uma condição associada com um excesso de taquicininas |
| JP2004250329A (ja) | 2002-12-26 | 2004-09-09 | Dainippon Pharmaceut Co Ltd | イサチン誘導体 |
| US7135575B2 (en) | 2003-03-03 | 2006-11-14 | Array Biopharma, Inc. | P38 inhibitors and methods of use thereof |
| ES2340772T3 (es) | 2003-10-24 | 2010-06-09 | Eli Lilly And Company | Nuevas formas cristalinas (2-(1-(3,5-bis-trifluorometilbencil)-5-piridin-4-il-1h-(1,2,3)triazol-4-il)-piridin-3-il)-(2-clorofenil)-metadona. |
| JP4673068B2 (ja) | 2005-01-19 | 2011-04-20 | 独立行政法人科学技術振興機構 | Ｔｈ１型アレルギー疾患治療用組成物 |
| DE102005006217B4 (de) | 2005-02-07 | 2007-08-16 | Universitätsklinikum Hamburg-Eppendorf | Diagnose von allergischen Erkrankungen und/oder atopischen Erkrankungen durch Nachweis von Autoantikörpern gegen CD28 in humanem Serum |
| CA2643130A1 (en) | 2006-02-22 | 2007-08-30 | Valorisation Recherche Hscm, Limited Partnership | Compounds and methods of treating disorders associated with activation of metachromatic cells |
| PT2121610E (pt) | 2006-12-20 | 2014-06-25 | Lilly Co Eli | Novos intermediários e processo útil para a preparação da {2-[1-(3,5-bis-trifluorometil-benzil)-5-piridin-4-il-1h-[1,2,3]triazol-4-il]-piridin-3-il}-(2-clorofenil)-metanona |
| JP6644328B2 (ja) | 2013-02-28 | 2020-02-12 | ロート製薬株式会社 | アトピー性疾患の発症又は重症化リスクの評価法 |
| US8906951B1 (en) | 2013-06-24 | 2014-12-09 | Tigercat Pharma, Inc. | Use of NK-1 receptor antagonists in pruritus |
| KR20160023692A (ko) | 2013-06-24 | 2016-03-03 | 타이거캣 파마, 인크. | 소양증에서의 nk-1 수용체 길항제 세를로피탄트의 용도 |
| BR112017018620A2 (pt) * | 2015-03-04 | 2018-04-17 | Vanda Pharmaceuticals Inc. | método de administração de tradipitanto, e, tradipitanto. |
| US10821099B2 (en) | 2018-09-28 | 2020-11-03 | Vanda Pharmaceuticals Inc. | Use of tradipitant in motion sickness |
-
2018
- 2018-08-30 CN CN201880059276.3A patent/CN111093671A/zh active Pending
- 2018-08-30 KR KR1020207010029A patent/KR20200054232A/ko not_active Application Discontinuation
- 2018-08-30 US US16/644,567 patent/US11549147B2/en active Active
- 2018-08-30 EP EP18778635.5A patent/EP3681505A1/en active Pending
- 2018-08-30 MX MX2020002852A patent/MX2020002852A/es unknown
- 2018-08-30 AU AU2018331267A patent/AU2018331267B2/en active Active
- 2018-08-30 JP JP2020515146A patent/JP7347743B2/ja active Active
- 2018-08-30 BR BR112020004964-6A patent/BR112020004964A2/pt unknown
- 2018-08-30 CA CA3073998A patent/CA3073998A1/en active Pending
- 2018-08-30 WO PCT/US2018/048825 patent/WO2019055225A1/en active Application Filing
-
2020
- 2020-02-27 IL IL272949A patent/IL272949A/en unknown
- 2020-03-12 CL CL2020000655A patent/CL2020000655A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2018331267A1 (en) | 2020-04-16 |
| US20210062262A1 (en) | 2021-03-04 |
| JP7347743B2 (ja) | 2023-09-20 |
| KR20200054232A (ko) | 2020-05-19 |
| IL272949A (en) | 2020-04-30 |
| BR112020004964A2 (pt) | 2020-09-15 |
| RU2020112222A (ru) | 2021-10-13 |
| MX2020002852A (es) | 2020-07-22 |
| US11549147B2 (en) | 2023-01-10 |
| EP3681505A1 (en) | 2020-07-22 |
| JP2020533381A (ja) | 2020-11-19 |
| WO2019055225A1 (en) | 2019-03-21 |
| CL2020000655A1 (es) | 2020-10-09 |
| CA3073998A1 (en) | 2019-03-21 |
| CN111093671A (zh) | 2020-05-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2018331267B2 (en) | Improved treatment of atopic dermatitis with tradipitant | |
| Morita et al. | HTR7 mediates serotonergic acute and chronic itch | |
| Busse et al. | Safety and efficacy of the prostaglandin D2 receptor antagonist AMG 853 in asthmatic patients | |
| Werth et al. | Brief Report: Pharmacodynamics, Safety, and Clinical Efficacy of AMG 811, a Human Anti–Interferon‐γ Antibody, in Patients With Discoid Lupus Erythematosus | |
| US11324735B2 (en) | Method of treatment with tradipitant | |
| Yoshida et al. | Skin barrier defects in atopic dermatitis: From old idea to new opportunity | |
| Pavord et al. | Clinical development of mepolizumab for the treatment of severe eosinophilic asthma: on the path to personalized medicine | |
| Drummond et al. | GM-CSF therapy in human caspase recruitment domain–containing protein 9 deficiency | |
| Chimenti et al. | Apremilast for the treatment of psoriasis | |
| Yen et al. | Identification of phenothiazine as an ETV1‑targeting agent in gastrointestinal stromal tumors using the Connectivity Map | |
| EA024450B1 (ru) | Молекулярно-генетический подход к лечению и диагностике алкогольной и наркотической зависимости | |
| Gutala et al. | Nicotine modulates expression of amyloid precursor protein and amyloid precursor-like protein 2 in mouse brain and in SH-SY5Y neuroblastoma cells | |
| US20230073637A1 (en) | Treatment of atopic dermatitis with tradipitant | |
| RU2793237C2 (ru) | Усовершенствованное лечение атопического дерматита традипитантом | |
| RU2812890C2 (ru) | Усовершенствованное лечение атопического дерматита традипитантом | |
| Laidlaw et al. | Trial of thromboxane receptor inhibition with ifetroban: TP receptors regulate eicosanoid homeostasis in aspirin-exacerbated respiratory disease | |
| US20200408771A1 (en) | Cd153 and/or cd30 in infection | |
| Akiyama et al. | IL-16 variability and modulation by antiallergic drugs in a murine experimental allergic rhinitis model | |
| Spears et al. | Factors influencing individual variability in the therapeutic response to corticosteroids in asthma | |
| Politiek | The Challenge of Hand Eczema: Pathogenesis, Treatment, and Burden of Disease | |
| Kuppusamy | Iron Status: A Possible Risk Factor for Febrile Seizures | |
| WO2020132513A1 (en) | Improved treatment of atopic dermatitis with tradipitant | |
| Renger | 0103 REM SLEEP IS INDUCED BY DUAL AND OREXIN 2 RECEPTOR ANTAGONISTS VIA MECHANISMS BEYOND ALPHA1-NORADRENERGIC SIGNALING | |
| KR20220145844A (ko) | 트라디피탄트를 이용한 아토피 피부염의 개선된 치료 | |
| Gendron et al. | Phosphorylated neurofilament heavy chain: a biomarker of survival for C9ORF72 |